Presage Biosciences
About
Presage Biosciences develops a technology platform to improve the cancer drug development process.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $7M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Nov 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 2, 2021 | Series Unknown | $7M | 1 |
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series Unknown |
